晚发性庞贝病患者血液中抗体水平和生物标志物的研究
晚发庞贝病患者 AAV8 抗体血清阳性率和生物标志物评估的研究
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards.
The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time.
Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold.
The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells.
Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers.
In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There will be 2 groups - those who have never had enzyme replacement therapy, and those who have had enzyme replacement therapy for 6 months or more. No study treatment will be given during the study, but blood and urine samples will be taken for testing.
The main aims of the study are to check antibody levels against AAV8 (a type of AAV) in people with late-onset Pompe disease who had not received any treatment using AAV, to check antibody levels against the GAA enzyme in people previously treated with GAA as part of enzyme replacement therapy, to check levels of biomarkers for Pompe disease, and to check for medical problems.
In the study, people will visit the study clinic several times. Some visits may be in the person's home. The first visit is to check if they can take part. Those who can take part will have a medical examination, and have their vital signs checked. Vital signs include blood pressure, heart rate, breathing rate and temperature. Blood samples will be taken to check antibody levels against the GAA enzyme and against AAV8. Blood and urine samples will also be taken to check for biomarkers for Pompe disease. Blood and urine samples will be taken about every 4 months for up to 2 years.
研究概览
详细说明
No investigational drug will be administered to participants in this study. Blood and urine will be collected as part of the study. The duration of the study is approximately 2 years, participants may withdraw at any time.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Edmonton、加拿大
- CN15003
-
Montreal、加拿大
- CA15001
-
-
-
-
-
Taipei、台湾
- TW88601
-
Taipei、台湾
- TW88602
-
Taoyuan City、台湾
- TW88603
-
-
-
-
-
Flamengo、巴西
- BR55003
-
Porto Alegre、巴西
- BR55002
-
São Paulo、巴西
- BR55001
-
-
-
-
-
Bonn、德国
- DT49005
-
Essen、德国
- DT49004
-
Höchheim、德国
- DT49003
-
Münster、德国
- DT49006
-
-
-
-
-
Florence、意大利
- IT39002
-
Gussago、意大利
- IT39005
-
Messina、意大利
- IT39012
-
Milan、意大利
- IT39009
-
Milan、意大利
- IT39011
-
Pavia、意大利
- IT39008
-
Pisa、意大利
- IT39006
-
Roma、意大利
- IT39004
-
Udine、意大利
- IT39003
-
-
-
-
-
Kodaira-Shi、日本
- National Center of Neurology and Psychiatry
-
Shinjuku-Ku、日本
- Tokyo Women's Medical University Hospital
-
-
-
-
-
Angers、法国
- FR33006
-
Garches、法国
- FR33009
-
Lille、法国
- FR33005
-
Limoges、法国
- FR33007
-
Marseille、法国
- FR33002
-
Nantes、法国
- FR33003
-
Nice、法国
- FR33004
-
Strasbourg、法国
- FR33001
-
-
-
-
-
Adelaide、澳大利亚
- AU61003
-
Herston、澳大利亚
- AU61001
-
-
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Emory Clinic
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- University of Kansas Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55404
- Children's Hospitals and Clinics of Minnesota
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
-
Ohio
-
Cincinnati、Ohio、美国、45221
- University of Cincinnati
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15213
- University of Pittsburgh Medical Center
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- University of UTAH - PPDS
-
-
Virginia
-
Fairfax、Virginia、美国、22030
- Lysosomal and Rare Diseases Research and Treatment Center, Inc.
-
-
-
-
-
Cambridge、英国
- UK44003
-
Newcastle upon Tyne、英国
- UK44001
-
Salford、英国
- UK44004
-
-
-
-
-
Albacete、西班牙
- ES34003
-
Barcelona、西班牙
- ES34004
-
Donostia / San Sebastian、西班牙
- ES34009
-
L'Hospitalet de Llobregat、西班牙
- ES34007
-
Madrid、西班牙
- ES34001
-
Madrid、西班牙
- ES34005
-
Valencia、西班牙
- ES34002
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant has a documented clinical diagnosis of LOPD.
- Participant is enzyme replacement therapy ERT-naïve (ERT-N) or if the participant is currently taking an approved ERT treatment or is participating in an ERT-interventional study, the ERT must have been received for at least 6 months or more (ERT-experienced [ERT-E]).
- Participant is willing and able to comply with study visits and procedures.
- Participant agrees to not start participating in any other clinical study involving an investigational study treatment, including ERT, while participating in this study.
Exclusion Criteria:
- Participant previously received an AAV-related product (any serotype).
- Participant is currently participating in a Pompe-related interventional study (other than ERT-interventional studies) or has received gene or cell therapy.
- Participant requires any invasive or noninvasive ventilation support while awake and upright (non-invasive support while sleeping with either continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) is acceptable for eligibility).
- Participant is unable to ambulate (assistive devices [e.g., cane or walker] are acceptable for eligibility).
- Participants who have received any ERT for less than 6 months as of the Baseline visit are not eligible.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Participants with Late-Onset Pompe Disease
Adolescent or adult participants with LOPD. |
No investigational drug will be administered to participants in this study. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Occurrence of total antibodies to AAV8
大体时间:Up to 2 years
|
Antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
|
Occurrence of neutralizing antibodies to AAV8
大体时间:Up to 2 years
|
Antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Seroconversion of antibodies to AAV8 over time
大体时间:Up to 2 years
|
Seroconversion of antibodies to AAV8 will be recorded from serum blood samples collected. |
Up to 2 years
|
|
Creatine kinase [CK] levels
大体时间:Up to 2 years
|
CK levels will be recorded from blood plasma samples collected. |
Up to 2 years
|
|
Urine glucose tetrasaccharide [Glc4]/hexose tetrasaccharide [Hex4] over time
大体时间:Up to 2 years
|
Glc4/Hex4 will be recorded from urine samples collected. |
Up to 2 years
|
|
Occurrence of anti-GAA antibodies in participants on ERT
大体时间:Up to 2 years
|
Anti-GAA antibodies will be recorded from serum blood samples collected. |
Up to 2 years
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Astellas Gene Therapies
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- AT845-02
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.